Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accounts Payables (2016 - 2025)

Tg Therapeutics has reported Accounts Payables over the past 10 years, most recently at $107.5 million for Q4 2025.

  • Quarterly results put Accounts Payables at $107.5 million for Q4 2025, up 84.42% from a year ago — trailing twelve months through Dec 2025 was $107.5 million (up 84.42% YoY), and the annual figure for FY2025 was $107.5 million, up 84.42%.
  • Accounts Payables for Q4 2025 was $107.5 million at Tg Therapeutics, down from $112.3 million in the prior quarter.
  • Over the last five years, Accounts Payables for TGTX hit a ceiling of $134.0 million in Q2 2025 and a floor of $29.7 million in Q3 2022.
  • Median Accounts Payables over the past 5 years was $54.2 million (2021), compared with a mean of $68.2 million.
  • Biggest five-year swings in Accounts Payables: plummeted 33.5% in 2022 and later soared 155.17% in 2024.
  • Tg Therapeutics' Accounts Payables stood at $51.3 million in 2021, then fell by 18.08% to $42.0 million in 2022, then fell by 8.44% to $38.5 million in 2023, then soared by 51.53% to $58.3 million in 2024, then soared by 84.42% to $107.5 million in 2025.
  • The last three reported values for Accounts Payables were $107.5 million (Q4 2025), $112.3 million (Q3 2025), and $134.0 million (Q2 2025) per Business Quant data.